Cancer Gene Therapy

Dewey R.A., Morrissey G., Cowsill C.M., Stone D., Bolognani F., Dodd N.J., Southgate T.D., Klatzmann D., Lassmann H., Castro M.G., Lowenstein P.R. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med. 5:1256-1263,1999. Click here for the PDF
Ambar, B.B., Frei, K., Malipiero, U., Morelli, A.E., Castro, M.G., Lowenstein, P.R. and Fontana A. Treatment of experimental glioma by administration of adenoviral vectors. Human Gene Therapy, 10: 1641-1648, 1999. Click here for the PDF
Cowsill, C., Southgate, T.D., Morrissey, G., Dewey, R.A., Morelli, A.E., Maleniak, T.C., Klatzmann, D Forrest, Z., D., Wilkinson, G.W.G., Lowenstein, P.R. and Castro, M.G. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK. Gene Therapy, 7: 679-685, 2000. Click here for the PDF
Glaser, T., Castro, M.G., Lowenstein, P.R., and Weller, M. Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase 1 cytotoxicity in LN-18 and LN-229 human malignant glioma cells. Gene Therapy 8: 469-476, 2001. Click here for the PDF
Maleniak, T.C., Darling, J.L., Lowenstein, P.R., and Castro, M.G. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Therapy, 8: 589-598, 2001. Click here for the PDF
Cowen, R. L., J. C. Williams, S. Emery, D. Blakey, J. L. Darling, P. R. Lowenstein and M. G. Castro (2002). "Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane." Cancer Gene Ther 9(11): 897-907. Click here for the PDF
Solly, S. K., S. Trajcevski, C. Frisen, G. W. Holzer, E. Nelson, B. Clerc, E. Abordo-Adesida, M. Castro, P. Lowenstein and D. Klatzmann (2003). "Replicative retroviral vectors for cancer gene therapy." Cancer Gene Ther 10(1): 30-9. Click here for the PDF
Zermansky AJ, Bolognani F, Stone D, Cowsill CM, Morrissey G, Castro MG, Lowenstein PR."Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS." Mol Ther. 2001 Nov;4(5):490-8. Click here for the PDF
Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG."Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas." Mol Ther. 2001 Dec;4(6):593-602. Erratum in: Mol Ther 2002 Feb;5(2):211. Click here for the PDF
Castro M, Goverdhana S, Hu J, Jovel N, Yuan X, Lowenstein P."Gene therapy for pituitary tumors: from preclinical models to clinical implementation." Front Neuroendocrinol. 2003 Jan;24(1):62-77 Click here for the PDF
Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR."Current and future strategies for the treatment of malignant brain tumors." Pharmacol Ther. 2003 Apr;98(1):71-108 Click here for the PDF
Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR."Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model." Cancer Gene Ther. 2004 Nov;11(11):721-32. Click here for the PDF
Ali S, Curtin JF, Zirger JM, Xiong W, King GD, Barcia C, Liu C, Puntel M, Goverdhana S, Lowenstein PR, Castro MG."Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression." Mol Ther. 2004 Dec;10(6):1071-84. Click here for the PDF
Ali S, King GD, Curtin JF, Candolfi M, Xiong W, Liu C, Puntel M, Cheng Q, Prieto J, Ribas A, Kupiec-Weglinski J, van Rooijen N, Lassmann H, Lowenstein PR, Castro MG."Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model." Cancer Res. 2005 Aug 15;65(16):7194-204.
Click here for the PDF
Curtin JF, King GD, Candolfi M, Greeno RB, Kroeger KM, Lowenstein PR, Castro MG."Combining cytotoxic and immune-mediated gene therapy to treat brain tumors."
Curr Top Med Chem. 2005;5(12):1151-70. Click here for the PDF
King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG."Gene therapy and targeted toxins for glioma." Curr Gene Ther. 2005 Dec;5(6):535-57. Click here for the PDF
Candolfi M, Curtin JF, Xiong W, Kroeger KM, Liu C, Rentsendorf A, Agadjanian H, Medina-Kauwe L, Palmer D, Ng P, Lowenstein PR, Castro MG, (2006) Effective high capacity gutless adenoviral vectors mediate transgene expression in human glioma cells. Molecular Therapy, 14(3):371-81. Click here for the PDF
Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, Curtin JF, McNiel EA, Freese AB, Ohlfest JR, Moore P, Lowenstein PR, Castro MG.(2007)"Adenoviral-mediated gene transfer into the canine brain in vivo" Neurosurgery; 60(1):167-77 Click here for the PDF
Candolfi Marianela, G. Elizabeth Pluhar,Kurt Kroeger, Mariana Puntel, James Curtin, Carlos Barcia, AKM Ghulam Muhammad, Weidong Xiong, Chunyan Liu,Sonali Mondkar, William Kuoy, Terry Kang, Elizabeth A. McNeil, Andrew B. Freese, John R. Ohlfest, Peter Moore, Donna Palmer, Phillip Ng, John D. Young,Pedro R. Lowenstein, Maria G. Castro. "Optimization of adenoviral vector mediated expression in the canine brain in vivo, and in canine glioma cells in vitro." Neuro-Oncology; In Press, 2007 Click here for the PDF
Gwendalyn D. King, AKM Ghulam Muhammad, James F. Curtin, Carlos Barcia, Mariana Puntel, Chunyan Liu, Sarah B. Honig, Marianela Candolfi, Sonali Mondkar, Pedro R. Lowenstein, Maria G. Castro. "Flt3L and TK gene therapy eradicate multifocal glioma in a
syngeneic glioblastoma model" Neuro-Oncology; In Press, 2007
Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, McNiel EA, Ohlfest JR, Freese AB, Moore PF, Lerner J, Lowenstein PR, Castro MG., (2007) J Neurooncol. 2007 Nov;85(2):133-48 Click here for the PDF
Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, Castro MG, Lowenstein PR, Freese A, Ohlfest JR. Efficacy of nonviral gene transfer in the canine brain. J Neurosurg. 2007 Jul;107(1):136-44. Click here for the PDF
Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR, Castro MG, Hall WA, Ohlfest JR. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg. 2007 Sep;107(3):568-77.
King GD, Muhammad AK, Curtin JF, Barcia C, Puntel M, Liu C, Honig SB, Candolfi M, Mondkar S, Lowenstein PR, Castro MG. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol. 2008 Jan;10(1):19-31 Click here for the PDF
King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol. 2008 May;82(9):4680-4. Epub 2008 Feb 20. Click here for the PDF
King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, Castro MG. Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther. 2008 Apr;16(4):682-90. Epub 2008 Feb 19. Click here for the PDF
Curtin JF, Candolfi M, Xiong W, Lowenstein PR, Castro MG. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther. 2008 Mar;7(3):439-48. Click here for the PDF
Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, Lowenstein PR, Castro MG. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE. 2008 Apr 23;3(4):e1983. Click here for the PDF